Simone van Broekhoven’s Post

Our latest article "Integrated Bioanalysis Strategies in Nonclinical Early In-Vivo PK studies of siRNAs" examines critical aspects of siRNA analysis during preclinical studies, including exposure levels, tissue distribution, the concentration of RNA-induced silencing complexes, and more. It also explores the world of small interfering RNAs (siRNAs) and their transformative role in gene regulation. Plus, we included a case study to demonstrate the methodology's effectiveness in early drug development of siRNA. Learn more: https://hubs.li/Q02gkq8T0 #dmpk #bioanalysis #siRNA #pharmacokinetics #drugdevelopment

Want a first look at our innovative platform for unlocking patient access to life-saving cell and gene therapies? Heading to ISCT, International Society for Cell & Gene Therapy's conference in Vancouver? Then book a live demo with the Ori Biotech team here - https://lnkd.in/eANBmhCP Not lucky enough to be joining, but still want to check it out? Sneaky peek below 👇

Our latest article "Integrated Bioanalysis Strategies in Nonclinical Early In-Vivo PK studies of siRNAs" examines critical aspects of siRNA analysis during preclinical studies, including exposure levels, tissue distribution, the concentration of RNA-induced silencing complexes, and more. It also explores the world of small interfering RNAs (siRNAs) and their transformative role in gene regulation. Plus, we included a case study to demonstrate the methodology's effectiveness in early drug development of siRNA. Learn more: https://hubs.li/Q02gkkfx0 #dmpk #bioanalysis #siRNA #pharmacokinetics #drugdevelopment

#OrigiGator Genascence Corporation, a clinical-stage #biotech company, announced the Phase 1 #clinicaltrial data for its osteoarthritis treatment at the European Society of Gene and Cell Therapy 30th Annual Congress. 🧬 They were able to demonstrate that the drug met the primary safety endpoint and was well-tolerated in all study subjects. They also noted encouraging symptomatic improvements! 📈 This is the first step for bringing the tech, licensed from University of Florida College of Medicine's Dr. Steven Ghivizzani, to market. 💉 Learn more, here. ▶️ https://lnkd.in/erdyD-_U

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3V6gqd4 While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3V6gqd4

Hope to see you there! My colleagues Pouria Motevalian and Amy Lavelle will be presenting on these hot topics - scaling up gene therapy processes & analytical strategy #asgct2024

Are you going to the American Society of Gene & Cell Therapy (#ASGCT) 27th Annual Meeting in #Baltimore, Maryland from May 7-11? If so, be sure to attend Thermo Fisher Scientific's sponsored session on Friday, May 10 at 8 a.m. EDT: “Revolutionizing #genetherapy services: A synergistic approach to analytics and scaling up through CDMO-CRO collaboration.” This session will explore the possibilities of adeno-associated viral (#AAV) vectors as widely-used carriers for #genetherapy medicinal products (#GTMPs). It will also discuss the challenges in #scalability and #analytics during AAV production that may limit their impact. Additionally, it will cover how strategic CDMO-CRO collaborations can help address these hurdles. Learn more about this sponsored session here: http://spr.ly/6044brBXa

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3KbQEOm While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3KbQEOm

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

A coordinated orchestration with tailored services, distribution and advanced analytics is critical to unlocking value for our CGT partners.